Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : VTA-100
Therapeutic Area : Genetic Disease
Study Phase : IND Enabling
Sponsor : Cambrian Biopharma
Deal Size : $32.0 million
Deal Type : Series A Financing
Vita Therapeutics Raises $32 Million in Oversubscribed Series A Financing
Details : Vita’s lead therapy, VTA-100, is currently undergoing investigational new drug (IND)-enabling studies for the treatment of limb-girdle muscular dystrophy (LGMD) 2A/R1.
Brand Name : VTA-100
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 23, 2021
Lead Product(s) : VTA-100
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Sponsor : Cambrian Biopharma
Deal Size : $32.0 million
Deal Type : Series A Financing
LOOKING FOR A SUPPLIER?
Reset All
